Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial
Go here to read the rest:
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology...
Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials
Read the rest here:
Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research
New Random Integration Transgenic Animal Model Generation Solution Available New Random Integration Transgenic Animal Model Generation Solution Available
Read more:
Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio
SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the “Test”) for the detection of SARS?CoV-2 neutralizing antibodies. This application marks AXIM’s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response.
See original here:
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19...
Company recognized for innovative and effective use of real-world data and flexible trial designs Company recognized for innovative and effective use of real-world data and flexible trial designs
Read the original here:
Parexel Named Best Contract Research Organization by Scrip
Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US
BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.
The rest is here:
Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces the publication of the results of a two-year research collaboration with the University College of London (UCL) Institute of Ophthalmology. The results showed that the therapeutic intravitreal (IVT) administration of long-acting nomacopan mitigated both the severity and progress of retinal damage in two models of autoimmune uveitis, a severe inflammatory eye disease where steroids are the primary treatment option. In addition, results showed the presence of inflammatory cells expressing both complement C5 and LTB4 receptors in retinal tissue from donor patients with uveitis as compared to healthy donor eyes.
Originally posted here:
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal...
Read the original:
Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand
Continue reading here:
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
NANTES, France, Dec. 03, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de Nantes) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104, a monoclonal antibody CD28 antagonist, in patients undergoing renal transplant. This study will be conducted as part of a collaboration agreement between OSE Immunotherapeutics and the University Hospital of Nantes.
Continue reading here:
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company’s systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.
Read the original here:
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
SALINAS, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announces updated guidance for the fourth quarter ending December 31, 2020. All figures stated are in US Dollars.
Visit link:
Indus Holdings, Inc. Announces Updated Fourth Quarter Guidance
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET
Follow this link:
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that:
See original here:
GENFIT announces satisfactory preliminary results of its OCEANEs’ partial buyback offer
OKLAHOMA CITY, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO™ manufacturing platform. This announcement is on the heels of Cytovance launching its Keystone Expression System® pDNA manufacturing licensing program.
Go here to see the original:
Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing
Company announcement – No. 57 / 2020
See original here:
Total number of shares and voting rights in Zealand Pharma at November 30, 2020
